Last $1.97 USD
Change Today +0.05 / 2.60%
Volume 82.6K
APRI On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

apricus biosciences inc (APRI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/30/13 - $2.71
52 Week Low
11/5/13 - $1.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

apricus biosciences inc (APRI) Related Bloomberg News

View More Bloomberg News

apricus biosciences inc (APRI) Related Businessweek News

No Related Businessweek News Found

apricus biosciences inc (APRI) Details

Apricus Biosciences, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for men’s and women’s health. The company’s lead product, Vitaros, has approved for the treatment of erectile dysfunction in Canada and Europe. It is also developing Vitaros product candidate (room temperature Vitaros) that is a proprietary stabilized dosage formulation, which can be stored at room temperature conditions. The company’s product candidate in the areas of women’s health includes Femprox, an alprostadil-based cream product candidate intended for the treatment of female sexual interest/arousal disorder that has completed an approximately 400-subject proof-of-concept study. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

21 Employees
Last Reported Date: 03/17/14
Founded in 1987

apricus biosciences inc (APRI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $477.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $421.2K
Vice President of Commercial Development
Total Annual Compensation: $229.7K
Compensation as of Fiscal Year 2013.

apricus biosciences inc (APRI) Key Developments

Apricus Biosciences, Inc. Presents at BIO International Convention, Jun-24-2014 03:30 PM

Apricus Biosciences, Inc. Presents at BIO International Convention, Jun-24-2014 03:30 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Apricus Biosciences Launches Erectile Dysfunction Treatment in UK

Apricus Biosciences has launched an on-demand treatment for erectile dysfunction called Vitaros. The company announced that Vitaros will be marketed in the United Kingdom by Takeda Pharmaceuticals International GmbH. The erectile dysfunction market in the United Kingdom was approximately $200 million in 2013 based on prescription sales, making it one of the larger erectile dysfunction markets in Europe. The European PDE-5 inhibitor market is approximately $1.5 billion as estimated by IMS Health, and analyst estimates for ex-US Vitaros sales are in the range of $300 million at peak. Apricus announced that it had received multiple commercial product orders of Vitaros from its partners and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The company announced that commercialization of Vitaros has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.

Leonard Oppenheim Not to Stand for Re-Election as Director of Apricus Biosciences

At the Annual Meeting of Stockholders of Apricus Biosciences, Inc. held on May 15, 2014, Leonard Oppenheim's term as a member of the Company's Board of Directors expired. Mr. Oppenheim elected not to stand for re-election at the Annual Meeting for personal reasons and his retirement from the Board was not related to a disagreement with the Company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APRI:US $1.97 USD +0.05

APRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $63.78 USD -0.59
GlaxoSmithKline PLC 1,423 GBp -46.50
Pfizer Inc $30.19 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation APRI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.0x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APRICUS BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at